StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen KANJINTI (trastuzumab-anns by Quarter

KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

Amgen KANJINTI (trastuzumab-anns: $42M in Q4 2023, down 33.3% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
42
Period ended Dec 31, 2023
Change on a year earlier
-33.3%
63 in Q4 2022
History
21 quarters
Since Q4 2018
Sources
17
Documents cited below

Where the Q4 2023 figure comes from

“|| KANJINTI ® | 31 | 11 | 42 | 63 | (33%)”

Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202342-33.3%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202320-72.2%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202350-41.2%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202347-51.0%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202263-54.7%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202272-37.9%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202285-45.5%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202296-40.4%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021139-12.0%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021116-30.5%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 2021156+26.8%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 2021161+35.3%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 2020158+53.4%Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 2020167+142.0%Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 2020123+310.0%Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 2020119+395.8%Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗

Breakdown

What makes up KANJINTI (trastuzumab-anns

Cite this data

StockData. (2026). Amgen KANJINTI (trastuzumab-anns ($M), quarterly Q4 2018–Q4 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kanjinti-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.